• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

by Sarah Moniz | Apr 10, 2018

Time for T? Immunoinformatics addresses the challenges of vaccine design for neglected tropical and emerging infectious diseases

Time for T? Immunoinformatics addresses the challenges of vaccine design for neglected tropical and emerging infectious diseases

by Adam | Oct 22, 2016

Expert Review of Vaccines. Resubmitted 3 Aug 2014. Full Text
An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2015;11(9):2322-8 .PMID: 26107442
Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma

by Adam | Oct 22, 2016

Vaccine. 2015;33(10):1256-66 PMCID: PMC4331251
Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

Preclinical development of HIvax: human survivin Highly Immunogenic vaccines

by Adam | Oct 22, 2016

« Older Entries

Recent Posts

  • Keeping Tolerance in Focus: Treg Control of ADA Depends on Clinical Context
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
  • EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.